(Lexatumumab)Biosimilar Reference Antibody-GS40381

货号：GS40381

Lexatumumab (also known as HGS-ETR2) is a fully human monoclonal antibody that specifically targets and activates TRAIL receptor 2 (TRAIL-R2, also known as DR5 or TNFRSF10B), a member of the tumor necrosis factor (TNF) receptor superfamily. As an agonist antibody, it binds to DR5 and mimics the action of the natural ligand TRAIL (TNF-related apoptosis-inducing ligand), thereby inducing apoptosis (programmed cell death) in cancer cells that express the receptor. It was developed as a potential therapeutic agent for the treatment of various advanced solid tumors and hematologic malignancies, based on the premise of selectively triggering cell death in tumors while sparing most normal cells.